The global primary aldosteronism market was valued at USD 1.78 billion in 2025. The market is projected to grow from USD 1.93 billion in 2026 to USD 3.62 billion by 2034, exhibiting a compound annual growth rate of 8.19% during the forecast period. Contrive Datum Insights presents this information in its report titled "Primary Aldosteronism Market Size, Share & Industry Analysis, By Type (Aldosterone-Producing Adenoma (APA), Bilateral Adrenal Hyperplasia (BAH)), Product type (Pharmaceuticals, Diagnostic Devices & Imaging Systems, Surgical & Adrenalectomy Devices), Treatment approach (Medical Management (Pharmacotherapy), Surgical Intervention (Adrenalectomy)), End user (Hospitals, Specialty Clinics & Endocrinology Centers, Diagnostic Imaging Centers, Ambulatory Surgical Centers), and Regional Forecast, 2026-2034".
Primary aldosteronism treatment covers the diagnostic and therapeutic pathway used once excess aldosterone production from the adrenal glands is suspected as the cause of a patient's hypertension, including biochemical screening, adrenal vein sampling and imaging used to distinguish unilateral adenoma from bilateral hyperplasia, and the medicines and surgical procedures used to treat each subtype. Purchasers span hospital endocrinology and interventional radiology departments, specialty endocrine clinics, diagnostic imaging centers, and the pharmacies and surgical centers that dispense mineralocorticoid receptor antagonist therapy or perform adrenalectomy. The category sits within the broader hypertension and endocrine disorder care pathway rather than as a stand-alone consumer product.
Rising diagnostic screening rates among resistant-hypertension patients
Rising diagnostic screening rates among resistant-hypertension patients is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 8.19% a year, the type lines exposed to it move fastest: Bilateral Adrenal Hyperplasia (BAH) compounds at 8.93%, taking its share of revenue from 57.87% to 61.88% and its value from USD 1.03 billion to USD 2.24 billion.
On the upside, the study's bull case assumes the bull case assumes faster-than-expected expansion of aldosterone-renin ratio screening into routine primary care hypertension workups, pulling more bilateral hyperplasia patients onto long-term pharmacotherapy sooner than the base forecast assumes, which would take 2034 revenue to USD 4.03 billion rather than the USD 3.62 billion base case.
However, the bear case assumes screening uptake stalls near current levels and adrenal vein sampling capacity constraints persist, leaving a larger share of primary aldosteronism cases undiagnosed and untreated through the forecast period, which would hold 2034 revenue to USD 3.14 billion. Aldosterone-Producing Adenoma (APA), which carries 42.13% of 2025 revenue, already grows at only 7.06% against the market's 8.19%, so the largest part of the base is also its slowest.
Key Players Compete on Bilateral Adrenal Hyperplasia (BAH) Volume and Bilateral Adrenal Hyperplasia (BAH) Growth
Competition in the global primary aldosteronism market runs along the type axis rather than the regional one. Bilateral Adrenal Hyperplasia (BAH) holds 57.87% of 2025 revenue at USD 1.03 billion and remains the largest line through 2034 at 61.88%, making it the position hardest for a challenger to take. Bilateral Adrenal Hyperplasia (BAH), growing at 8.93%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 1.78 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Bilateral Adrenal Hyperplasia (BAH) | 57.87% · USD 1.03 billion | — |
| Product type | Pharmaceuticals | 56.18% · USD 1 billion | — |
| Treatment approach | Medical Management (Pharmacotherapy) | 67.98% · USD 1.21 billion | — |
| End user | Hospitals | 43.82% · USD 0.78 billion | Specialty Clinics & Endocrinology Centers 9.31% |
- Based on regional analysis, North America led the global primary aldosteronism market in 2025 with 38.2% of global revenue at USD 0.68 billion, reaching USD 1.27 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 24.16% in 2025 to 27.9% in 2034, with revenue growing from USD 0.43 billion to USD 1.01 billion.
- Middle East and Africa remains the smallest region throughout, at 4.49% of 2025 revenue and 4.97% by 2034.
- Bilateral Adrenal Hyperplasia (BAH) is projected to grow at 8.93% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 0.56 billion in 2025, 31.46% of global revenue.
The report segments the market across four axes; by type, and by product type, treatment approach and end user; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 3.14 billion and USD 4.03 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.